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http://dx.doi.org/10.1016/j.jmii.2012Background: The fimbriae of Salmonella enterica serovar Enteritidis are used for colonization
and invasion into host cells, and have drawn considerable interest because fimbriae can serve
as potential immunogens against many pathogenic bacteria that colonize on epithelial
surfaces. The purpose of the study is to use a molecular adjuvant, C3d, to enhance the immu-
nogenicity of FimA proteins against Salmonella enterica serovar Enteritidis.
Methods: FimA of type I fimbriae from Salmonella enteritidis and FimA with one copy of mC3d,
two copies of mC3d2 and three copies of mC3d3 were cloned into the expression vector pCold-
TF. Soluble fusion proteins of FimA with different copy of mC3d were induced by IPTG and ex-
pressed into Escherichia coli BL21 (DE3). Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) showed that the recombinant proteins from pCold-TF-fimA, TF-
fimA-mC3d, TF-fimA-mC3d2, TF-fimA-mC3d3 were 70 kDa, 100 kDa, 130 kDa and 160 kDa,
respectively. The fusion protein was recognized by rabbit anti-fimbriae polyclonal antibodies,
and then visualized by goat anti-rabbit polyclonal antibodies with a chrome appearance by
enzyme-subtract interaction. The recombinant proteins were purified by Ni-TED (tris-carbox-
ymethyl ethylene diamine), immobilized metal ion affinity chromatography (IMAC). Balb/c
mice were subcutaneously immunized with the purified proteins and the immune response
was monitored by an enzyme-linked immunosorbent assay (ELISA) for FimA-specific antibody.
The immunized mice were challenged with a 10-fold LD50 dose (i.e., 100 CFU) of Salmonella
enterica serovar Enteritidis standard strain (SD-2) 1 week after the second immunization.eterinary Medicine, Yangzhou University, Yangzhou, China.
ahoo.com (H.-H. Musa), yzgqzhu@hotmail.com (G.-Q. Zhu).
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58 H.-H. Musa et al.Results: The immunized mice with the fusion proteins FimA-mC3d2 and FimA-mC3d3 had
increased levels of ELISA titer of antibody that were 2 and 4 logs, respectively, more immuno-
genic than the TF-FimA protein alone. The challenge results showed that immune protection
rate in the mice immunized with 10 mg of FimA, FimA-mC3d2, and FimA-mC3d3 were 50%,
75% and 100%, respectively.
Conclusion: We conclude that mC3d can be expressed in a prokaryotic vector and enhance the
immune response of the recombinant protein. FimA-mC3d3 is potentially a subunit vaccine
against S. enterica serovar Enteritidis infection.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The prevalence of Salmonella enterica serovar Enteritidis
has dramatically increased worldwide; it is reportedly the
most common serotype in the United States. Approximately
1000 people die of the infection each year.1 Fimbriae are
used for colonization and invasion into host cells. They have
drawn considerable interest because the fimbriae are
potential immunogens against many pathogenic bacteria
that colonize epithelial surfaces.2 The main fimbriae of
S. enterica serovar Enteritidis are SEF14, SEF17, and SEF21,
which are composed of SefA, AgfA, and FimA fimbrial
proteins, respectively.3 Because of fimbriae structure and
localization, they are excellent targets for the host immu-
nological system. Fimbria-based vaccines are hypothesized
to protect the host against the adherence of pathogens by
blocking the organisms from attaching to the intestinal
mucosa.4 Scientific interest has recently focused on effector
molecules generated by the innate immune response and on
their role in shaping acquired immunity.5 A recombinant
protein consisting of an antigen fused to C3d may elicit
a more robust immune response than the antigen alone.
Dempsey et al.6 demonstrated that a recombinant protein
containing three copies of C3d attached to the carboxy
terminus of hen egg lysozyme (HEL) could elicit a primary
immune response is 10,000-fold greater with the modified
HEL protein, compared to the unmodified HEL protein.
Similar results were achieved by conjugating C3d to viral,
bacterial, parasitic, and cellular (i.e., self) antigens.7,8
Three repeats of C3d conjugated to a soluble trimeric
form of the HIV-1 Env was more effective at inducing
neutralizing antibodies to primary isolates than plasmids
encoding for non-C3d conjugated Env glycoproteins.9,10
Purified E2 proteins fused to murine and bovine homolog
C3d3 were 10,000 more immunogenic than E2 alone or anti-
E2 antibodies neutralized virus infection.8,10 This immuni-
zation mode demonstrated the ability of C3d to enhance
secondary humoral (i.e., IgG) immune responses and the
maturation of antibody avidity, and the ability of the anti-
body to neutralize infection and stimulate B-cell prolifera-
tion.11,12 In previous studies, mC3d conjugated to
prokaryote antigen was expressed on a cell culture, whereas
in the present study mC3d conjugated to prokaryote antigen
was clones into a pCold-TF expression vector and success-
fully expressed in Escherichia coli BL21(DE3). We therefore
used the active C3d as a molecular adjuvant to enhance theimmunogenicity of FimA proteins against Salmonella
enterica serovar Enteritidis. This will help in the design of
more efficient vaccines against Salmonella enterica serovar
Enteritidis.
Materials and methods
Bacterial growth and DNA extraction
The Salmonella enterica serovar Enteritidis were cultured
overnight at 37C with vigorous agitation. The DNA then was
extracted. The FimA gene was amplified by an upper primer
with the NdeI restriction enzyme site: 50-CGC CATATG AAA
CAT AAA TTA ATG ACC TCT A-30 and a lower primer with the
NotI and BamHI restriction enzymes site: 50-TCG GCG GCC
GCG GAT CCT TCG TAT TTC ATG ATA AAG GTG-30. Poly-
merase chain reaction (PCR) was performed in a volume of
25 mL that contained 2.5 mL of the DNA template, 1.5 mL of
2.5 mM dNTP mixture, 2.5 mL of 10  PCR buffer, 1 mL upper
primer, 0.5 mL lower primer, 0.5 mL Ex Taq polymerase, and
16.5 mL sterilized distilled water. The PCR conditions were
an initial denaturing at 94C for 4 minutes, followed by 30
cycles at 94C for 1 minute. The product was annealed at
56C for 1 minute and extended at 72C for 1 minute. The
PCR product was finally extended at 72C for 10 minutes.
The 550 bp of the FimA gene was excised from the gel and
purified using DNA purification kit. The purified product was
then cloned into the PMD18-T simple vector and trans-
formed into Escherischia coli DH5a-competent cells.
Recombinant plasmids were extracted and analyzed by
restriction enzyme digestion and sequencing.
Construction of recombinant protein
The recombinant plasmids PMD18-T-FimA and the expres-
sion vector pCold TF were digested with NdeI and BamHI
restriction enzymes. The FimA gene and pCold TF expres-
sion vector both recovered from the gel in the agarose gel
DNA purification kit. Purified FimA DNA was cloned into
pCold-TF expression vector. The recombinant FimA-pCold-
TF was transformed into the E. coli DH5a-competent cells;
the positive clones were selected and determined by
restriction enzyme analysis with NdeI and BamHI.
The clones of C3d into the pUC plasmid were generated
according to the strategy of Dempsey et al6 and were a gift
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of Pennsylvania (Philadelphia, PA). Each C3d was connected
with a linker sequence encoding glycine/serine repeats, GS
(G4S)2 GS, in which potential proteolytic cleavage sites
were mutated by BamH1 and BglII fusion to mutate an
arginine to a glycine. The plasmids were digested with
BamHI and BglII to release the BLc3d, BLc3d2, and BLc3d3
fragments. The clones positive for pCold-TF-fimA were
similarly digested with BamHI. The digested products were
recovered from the gel by using an agarose gel DNA purifi-
cation kit. The BLc3d, BLc3d2, and BLc3d3 fragments were
then respectively cloned into the pCold-TF-fimA. The
recombinant protein was transformed into E. coli DH5a-
competent cells, and the positive clones were selected
and determined by PCR and restriction enzyme analysis
with NdeI and BamHI.Recombinant protein expression
Two microliters of pCold-TF-fimA, pCold-TF-fimA-BLc3d,
pCold-TF-fimA-BLc3d2, and pCold-TF-fimA-BLc3d3 plasmid
were used to transform 200 mL E. coli BL21(DE3). The E. coli
BL21(DE3) carrying pCold-TF-fimA-BLc3d was grown on LB
plates containing 100 mg/mL ampicillin at 37C overnight.
The single clone was grown in 5 mL LB broth plus ampicillin
(50 mg/mL) at 37C to OD600 of 0.4e0.5. The culture was
refrigerated at 15C and allowed to stand for 30 minutes.
The culture was then split into two aliquots. One aliquot
was induced by IPTG to a final concentration of 0.1 mmol/L
at 15C for 24 hours and the other aliquot was not induced
(i.e., the control). Harvested cells harvested were lysed by
sonication and subjected to 8% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
(Fig. 1A).The protein on 8% SDS-PAGE was transferred on
a nitrocellulose membrane (0.35 mA/cm2).The fusion
protein was blocked with 10% nonfat dry milk and recog-
nized by rabbit anti-fimbriae polyclonal antibodies (1:100),
and later visualized by goat anti-rabbit polyclonal anti-
bodies (1:1500) with a chrome appearance by enzyme-
subtract interaction (Fig. 1B). The recombinant proteins
were separately purified by Ni-TED (tris-carboxymethyl
ethylene diamine), immobilized metal ion affinity chro-
matography (IMAC) (Fig. 1C).Figure 1. Recombinant protein expression. (A) Sodium dodec
recombinant proteins. 1. FimA. 2. Control vector. 3. FimA-mC
(B) Western blot analysis of the recombinant proteins. 1. FimA. 2. F
molecular weight marker. (C) SDS-PAGE analysis of purified recombi
mC3d3. M. High molecular weight marker.Immunization
Sixty 6-week-old healthy female BALB/c mice were
purchased from the Center for Comparative Medicine,
Yangzhou University (Sigma-Aldrich, Yangzhou, China).
Mice were immunized subcutaneously in the right rear flank
with purified FimA, FimA-mC3d, FimA-mC3d2 and FimA-
mC3d3 soluble protein prepared in 100 mL phosphate-
buffered saline (PBS) containing 0.1% globulin-free mouse
albumin (Sigma-Aldrich).10 The doses used for immuniza-
tion were 0.1 mg, 1 mg and 10 mg for each group, whereas
the control group was immunized by sterile saline. Mice
were boosted intraperitoneally on day 35 with 10 mg FimA
protein in incomplete Freund’s adjuvant (IFA, Sigma-
Aldrich). Nonlethal tail blood samples were collected 1 day
before immunization and weekly after immunization by tail
section. At the completion of the experiments, the mice
were sedated with sodium pentobarbital and euthanatized
by exsanguinations. Serum levels for FimA-specific antibody
were determined for individual mice by ELISA, and titers
are expressed as the geometric mean and standard error.
ELISA
Polystyrene microplates (Immulon 4 HBX; ThermoLabsys-
tems) were coated with 100 mL of purified FimA at 0.125 mg/
mL, samples were incubated with serially diluted sera from
the vaccinated mice. Peroxidase-conjugated goat anti-
mouse IgG HRP (1:6000 dilution) was used as the
secondary antibody. The reaction was visualized with
o-phenylenediamine (Sigma). End-point titers were calcu-
lated as the reciprocal of the last serum dilution that gave
a value 2.1-fold higher than the preimmune serum. Anti-
body titers below the cutoff of the assay were assigned an
arbitrary titer of one-half of the cutoff for calculation of
the geometric mean of the titers.
Infection protection assay
One week after the second immunization, the standard
strains of Salmonella enteritidis SD-2 bacteria cultures
made suspensions of 100 colony-forming units (CFU) per
200 mL in normal saline were intraperitoneally injected inyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for
3d3. 4. FimA-mC3d2. 5. FimA-mC3d. M. molecular marker.
imA-mC3d. 3. FimA-mC3d2. 4. FimA-mC3d3. M. Pre-stained low
nant proteins. 1. FimA. 2. FimA-mC3d. 3. FimA-mC3d2. 4. FimA-
60 H.-H. Musa et al.each group of mice. (A pretest confirmed that standard
strains of Salmonella enterica serovar Enteritidis SD-2
poison BALB/c mice at LD50 of 10 CFU) Pathological
changes in the experimental mice after the bacterial
injection was observed once every 12 hours for 7 days.
Clinical symptoms of dead mice in each group were
dissected and their mortality was recorded. Sterile collec-
tion of liver, kidney, spleen was made in the dead mice in
each group and placed in selenite cystine enrichment broth
(SC). Salmonella enterica serovar Enteritidis in different
organs was thereafter cultured for 24 hours, and 5 mL of the
enrichment broth was transferred onto MacConkey agar
plates to determine the number of colony-forming units.
The immune protection ratio was calculated as
a percentage of the number of surviving animal to the total
number of animals in the experimental group.Results
Construction of the recombinant proteins
In the present study soluble FimA protein fused to mC3d
was expressed in a prokaryotic expression vector. The
recombinant protein fused to mC3d was constructed as
follow: the fimA gene was amplified by PCR using a pair of
primers and the DNA template from Salmonella enterica
serovar Enteritidis standard strain SD-2 genomic DNA. The
PCR products of the fimA gene were digested and cloned
into the expression vector pCold-TF to constructFigure 2. Change in antibody titer in the immune groups. (A) Fim
of purified protein at 0.1 mg, 1 mg, and 10 mg were used for the exp
received an intraperitoneal boost on day 35 with 10 mg FimA proterecombinant plasmid pCold-fimA, which was confirmed by
restriction enzymes and sequencing. The different copies
of mC3d, mC3d2 and mC3d3 were obtained through the
digestion of recombinant plasmids pUC-mC3d, pUC-mC3d2
and pUC-mC3d3, and were cloned into the recombinant
plasmid pCold-fimA to construct the recombinant plasmids
(i.e., pCold-fimA-mC3d, pCold-fimA-mC3d2, and pCold-
fimA-mC3d3). The fusion protein was optimally induced by
IPTG at 15C for 24 hours and expressed. SDS-PAGE showed
that the recombinant proteins were 70 kDa, 100 kDa,
130 kDa, and 160 kDa (Fig. 1), respectively. The recombi-
nant proteins expressing FimA were recognized by rabbit
anti-fimbriae polyclonal antibodies, and then visualized by
goat anti-rabbit polyclonal antibodies with a chrome
appearance by enzyme-subtract interaction. The recombi-
nant proteins were separately purified by Ni-TED (tris-car-
boxymethyl ethylene diamine) immobilized metal ion
affinity chromatography (IMAC).
Immunization
Fig. 2 shows the changes in antibody titer in the different
immune groups. When the immunization dose was 10 mg,
FimA antibody levels in mice with FimA-mC3d2 and FimA-
mC3d3 fusion protein groups were elevated to two and four
times, compared with the FimA protein groups. In addition,
in the 10 mg immunization dose, the antibody level in FimA-
mC3d3 groups was increased by four times and two times,
compared to the FimA-mC3d and FimA-mC3d2 groups
(Fig. 3).A; (B) FimA-mC3d; (C) FimA-mC3d2; and (D) FimA-mC3d3. Doses
erimental group. Sterile saline was used for control group. Mice
in in incomplete Freund’s adjuvant (IFA; Sigma).
Figure 3. Change in antibody titer with the same immune dose in the immune groups. (A) 0.1 mg immune dose; (B) 1 mg immune
dose; and (C) 10 mg immune dose. Doses of purified protein at 0.1 mg, 1 mg, and 10 mg were used for the experimental group. Sterile
saline was used for the control group. Mice received an intraperitoneal boost on day 35 with 10 mg FimA protein in incomplete
Freund’s adjuvant.
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Examination of the dead mice showed Salmonella enterica
serovar Enteritidis pathological lesions. The challenge test
results showed that immune protection ratio in mice
immunized with 10 mg of FimA, FimA-mC3d, FimA-mC3d2
and FimA-mC3d3 were 50%, 50%, 75%, and 100%, respec-
tively (Fig. 4). Therefore, we confirm that C3d can enhance
the immune effects of the conjugated protein which are
expressed in prokaryotic vector. Further study of C3d as
a novel molecular adjuvant for a prokaryotic protein
vaccine and its application in the prevention of Salmonella
may be promising.Figure 4. Immune protection ratio in mice immunized with
10 mg of FimA, FimA-mC3d, FimA-mC3d2, and FimA-mC3d3.Discussion
The problem with pure recombinant or synthetic antigens
used in modern day vaccines is that they generally are
generally far less immunogenic than older style live or killed
whole organismvaccines.13 In the present study,weenhanced
the immunogenicity of FimA protein by using the molecular
adjuvant mC3d. The production of recombinant protein in
Escherichia coli is often hampered by low expression levels
and low solubility. A variety of methodologies have been
developed, including protein production at low temperature
and fusion protein expression using soluble protein tags.14 The
recombinant protein Fim A fused to mC3d was cloned into
pCold-TF vector and expressed in E. coli BL21 (DE3). The
protein expressed was confirmed by SDS-PAGE. The antige-
nicity of the recombinant proteins expressing FimA were
recognized by rabbit anti-fimbriae polyclonal antibodies, and
then visualized by goat anti-rabbit polyclonal antibodies with
achromeappearancebyusingenzymeesubstrate interaction.
The recombinant proteins were separately purified by Ni-TED
and IMAC. The pCold-GSTexpression systemwas applied to 10
proteins that could not beexpressedusing conventionalE. coli
expression methodologies, Nine of these proteins were
successfully obtained in the soluble fraction.14 This suggests
that the pCold-GST expression system can be utilized to
improve the expression and purification of various proteins.14
Fimbriae are surface appendages found onmany species of
Enterobacteriaceae and they display adhesive properties.15
Some fimbriae are considered virulence factors because
they initiate adherence, which is the first step in the
62 H.-H. Musa et al.colonization of host mucosal surfaces.16,17 Information
regarding the role of SEF17 and SEF21 fimbriae in serovar
Enteritidis pathogenesis is lacking.2 The factors that influence
fimbrial phase variation in vivo and influence variability in the
fimbriation of cells carrying an intact fimbrial operon are
unknown; therefore, it is difficult to evaluate the role of
fimbriae in pathogenesis.2
FimA is a potent inducer of pro-inflammatory cytokines
involved in tissue destruction.18 Immunization with FimA
protects rats against homologous bacterial challenge.19 In
addition, FimA immunization confers antibody mediated
protection against Streptococcus parasanguis endocarditis in
rats.20 Immunization with FimA protein has further been
shown to reduce Porphyromonas gingivalis-induced alveolar
bone loss in experimental rats,21 and to confer protection
against subsequent lethal infection with P. gingivalis in
mice.22 The purified recombinant FimA protein of Salmonella
enterica serovar Enteritidis was detected by Kisiela et al.3
They indicated that immunization of hens with FimA fimbrial
proteins of Salmonella Enteritidis induces a strong humoral
response. The levels of anti-FimA antibodies induced by
purified recombinant proteins are similar to that level ob-
tained with live bacteria.3 FimA fimbrial proteins of Salmo-
nella enterica serovar Enteritidis, in addition to inducing
a strong humoral response, can induce cellular response.23 In
the present study we showed that, when the immunization
dose was 10 mg, antibody levels in mice with FimA-mC3d2 and
FimA-mC3d3 fusion protein groups were elevated to two and
four times, compared to the FimA protein groups. The chal-
lenge test showed that the immune protection ratio in mice
with FimA, FimA-mC3d, FimA-mC3d2 and FimA-mC3d3 were
50%, 75% and 100%, respectively. Therefore, we confirm that
C3d can enhance the immune effects of the conjugated
protein that are expressed in a prokaryotic vector.
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